CR20110365A - Compuestos etanamínicos y su uso para tratar la depresión - Google Patents

Compuestos etanamínicos y su uso para tratar la depresión

Info

Publication number
CR20110365A
CR20110365A CR20110365A CR20110365A CR20110365A CR 20110365 A CR20110365 A CR 20110365A CR 20110365 A CR20110365 A CR 20110365A CR 20110365 A CR20110365 A CR 20110365A CR 20110365 A CR20110365 A CR 20110365A
Authority
CR
Costa Rica
Prior art keywords
ethanaminal
compounds
treat depression
cocoa
chips
Prior art date
Application number
CR20110365A
Other languages
English (en)
Spanish (es)
Inventor
Michael Balestra
Peter Bernstein
Glen E Ernst
William Frietze
John P Mccauley
David Nugiel
Lihong Shen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42288011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110365(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR20110365A publication Critical patent/CR20110365A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Confectionery (AREA)
CR20110365A 2008-12-24 2011-06-24 Compuestos etanamínicos y su uso para tratar la depresión CR20110365A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14067308P 2008-12-24 2008-12-24

Publications (1)

Publication Number Publication Date
CR20110365A true CR20110365A (es) 2011-08-09

Family

ID=42288011

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110365A CR20110365A (es) 2008-12-24 2011-06-24 Compuestos etanamínicos y su uso para tratar la depresión

Country Status (31)

Country Link
US (4) US8013165B2 (enExample)
EP (2) EP2610246A1 (enExample)
JP (1) JP5491524B2 (enExample)
KR (1) KR20110097996A (enExample)
CN (1) CN102333762B (enExample)
AR (1) AR074981A1 (enExample)
AU (1) AU2009330745B2 (enExample)
BR (1) BRPI0923476A2 (enExample)
CA (1) CA2748235A1 (enExample)
CL (1) CL2011001590A1 (enExample)
CO (1) CO6450688A2 (enExample)
CR (1) CR20110365A (enExample)
CU (1) CU24017B1 (enExample)
DO (1) DOP2011000205A (enExample)
EA (1) EA201190064A1 (enExample)
EC (1) ECSP11011161A (enExample)
GT (1) GT201100186A (enExample)
HN (1) HN2011001773A (enExample)
IL (1) IL213518A0 (enExample)
MX (1) MX2011006680A (enExample)
NI (1) NI201100131A (enExample)
NZ (1) NZ593282A (enExample)
PE (1) PE20120249A1 (enExample)
SA (1) SA109310013B1 (enExample)
SG (2) SG192510A1 (enExample)
SV (1) SV2011003962A (enExample)
TW (1) TWI442922B (enExample)
UA (1) UA106056C2 (enExample)
UY (1) UY32360A (enExample)
WO (1) WO2010074647A1 (enExample)
ZA (1) ZA201105441B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8013165B2 (en) 2008-12-24 2011-09-06 Astrazeneca Ab Ethanamine compounds and methods of using the same 545
CN112250676B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氧杂环化合物
CN112279843B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氮杂环化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422191A (en) * 1965-01-21 1969-01-14 Synergistics Inc Compositions and methods for tranquilization employing salts of n-morpholine ethanol
GB1427026A (en) 1972-11-20 1976-03-03 Ici Ltd Synthetic film materials
JPS5756474B2 (enExample) 1973-05-26 1982-11-30
US5455259A (en) * 1987-02-06 1995-10-03 Fisons Corporation Compounds for the treatment of neurodegenerative disorders
GB9320273D0 (en) 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
EP0356035B1 (en) 1988-08-12 1996-03-13 Astra Aktiebolag Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
JP2514855B2 (ja) 1990-08-08 1996-07-10 キッセイ薬品工業株式会社 光学活性なアラニンアニリド誘導体の酸付加塩
US5206248A (en) * 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
DK0612314T3 (da) * 1991-10-30 2000-05-29 Astra Ab 2-pyrazinylethylaminderivater og deres anvendelse som lægemidler
KR100259567B1 (ko) * 1992-04-03 2000-07-01 클래스 빌헬름슨 신경변성 질환 치료용 1-페닐-2-(2-피리디닐)에틸아민 에난티오머
IL120669A (en) * 1996-04-19 2001-04-30 Akzo Nobel Nv Benzoheterocyclic benzylamine derivatives and pharmaceutical compositions containing them
ATE229004T1 (de) 1997-03-31 2002-12-15 Korea Res Inst Chem Tech Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
SE9901077D0 (sv) 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901340D0 (sv) * 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
US8013165B2 (en) 2008-12-24 2011-09-06 Astrazeneca Ab Ethanamine compounds and methods of using the same 545

Also Published As

Publication number Publication date
PE20120249A1 (es) 2012-04-19
AU2009330745B2 (en) 2012-04-05
ECSP11011161A (es) 2011-07-29
CU24017B1 (es) 2014-07-30
CU20110141A7 (es) 2012-01-31
EA201190064A1 (ru) 2012-02-28
CO6450688A2 (es) 2012-05-31
US20100179199A1 (en) 2010-07-15
US20120115913A1 (en) 2012-05-10
MX2011006680A (es) 2011-07-12
US8013165B2 (en) 2011-09-06
CL2011001590A1 (es) 2012-06-22
IL213518A0 (en) 2011-07-31
GT201100186A (es) 2013-10-08
DOP2011000205A (es) 2011-07-15
SV2011003962A (es) 2012-01-06
CN102333762B (zh) 2014-06-11
CN102333762A (zh) 2012-01-25
SG192510A1 (en) 2013-08-30
UA106056C2 (uk) 2014-07-25
US9035065B2 (en) 2015-05-19
AU2009330745A1 (en) 2011-08-04
UY32360A (es) 2010-07-30
CA2748235A1 (en) 2010-07-01
JP5491524B2 (ja) 2014-05-14
US20130137731A1 (en) 2013-05-30
ZA201105441B (en) 2012-03-28
EP2391606A1 (en) 2011-12-07
HN2011001773A (es) 2014-08-18
SA109310013B1 (ar) 2013-07-28
EP2391606A4 (en) 2012-06-13
WO2010074647A1 (en) 2010-07-01
NI201100131A (es) 2012-03-19
AR074981A1 (es) 2011-03-02
EP2610246A1 (en) 2013-07-03
SG171928A1 (en) 2011-07-28
BRPI0923476A2 (pt) 2016-01-19
JP2012513993A (ja) 2012-06-21
NZ593282A (en) 2013-06-28
TWI442922B (zh) 2014-07-01
US20120277272A1 (en) 2012-11-01
TW201028149A (en) 2010-08-01
KR20110097996A (ko) 2011-08-31

Similar Documents

Publication Publication Date Title
CR20110480A (es) Proceso de fabricacion de producto de cacao
TWI449540B (en) Process for the production of an abuse-proofed dosage form
IL190388A0 (en) Process for production of delta-9-tetrahydrocannabinol
PL2349962T3 (pl) Sposób wytwarzania chlorofluorowodoroolefin
EG25753A (en) Process for the production of alcohols
WO2010147898A3 (en) Small molecule inhibitors of spleen tyrosine kinase (syk)
TW200621776A (en) Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
PL2297079T3 (pl) Proces wytwarzania kwasu glikolowego
PL2350300T3 (pl) Sposób wytwarzania lipidów z biomasy
MY150022A (en) Process for producing high flavour cocoa
BRPI0820976A2 (pt) Processos para produção de ácido succínico
EP2264144A4 (en) PROCESS FOR THE PREPARATION OF 5'-GUANYLIC ACID
WO2010028122A8 (en) Process for making bivalirudin
ES2627652T8 (es) Procedimiento para la fabricación de un conjunto de piedras de bisutería
WO2009005647A3 (en) Compounds and process to prepare chiral intermediates for synthesis of paroxetine
EP1861408A4 (en) PROCESS FOR PRODUCING HYDROCHLOROSILANES
WO2008075205A3 (en) Improved process for the preparation of voriconazole
BRPI1008105A2 (pt) Processo para preparação de farelo de chocolate.
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
CR20110365A (es) Compuestos etanamínicos y su uso para tratar la depresión
IL243809A (en) Process for the production of γ-ketosulfide compounds and γ-ketosulfide compounds obtained
DE112009000076A5 (de) Verfahren zur Herstellung von Urethanen
IL187155A0 (en) Process for production of 4-biphenylazetidin-2-ones
MX2010009931A (es) Proceso para la preparacion de 2-amino-2-[2-(4-c3-c21-alquil-fenil )-etil]-propano-1,3-dioles.
ZA200710066B (en) Process for production of 4-biphenylylazetidin-2-ones